MaxCyte, Inc.
Price Action
Technical Summary
CONSOLIDATINGMaxCyte, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 80), indicating clear outperformance against the broad market. Earnings growth of 56% provides fundamental context to the price action. However, price is extended 20% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.18 | +4.93% | ABOVE |
| 50 SMA | $1.03 | +20.28% | ABOVE |
| 100 SMA | $0.90 | +37.85% | ABOVE |
| 150 SMA | $1.08 | +14.66% | ABOVE |
| 200 SMA | $1.21 | +2.70% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is MXCT in an uptrend right now?
MXCT has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is MXCT overbought or oversold?
MXCT's RSI (14) is 65. The stock is in neutral territory, neither overbought nor oversold.
Is MXCT outperforming the market?
MXCT has a Relative Strength (RS) Rating of 80 out of 99. Yes, MXCT is a market leader, outperforming 80% of all stocks over the past 12 months.
Where is MXCT in its 52-week range?
MXCT is trading at $1.24, which is 52% of its 52-week high ($2.37) and 34% above its 52-week low ($0.66).
How volatile is MXCT?
MXCT has a Beta of 1.58 and 52-week volatility of 74%. It's more volatile than the S&P 500 - expect bigger swings.